Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.
暂无分享,去创建一个
[1] M. Toi,et al. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report , 2003, The Journal of Steroid Biochemistry and Molecular Biology.
[2] E. Dejana,et al. Inhibitors of Cyclo-Oxygenase , 1983 .
[3] A. Barkun,et al. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. , 2003, Gastroenterology.
[4] S. Narumiya,et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. , 2002, Cancer research.
[5] B. Levin,et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.
[6] D. A. Dixon,et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. , 2001, The Journal of clinical investigation.
[7] F. Marks,et al. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[8] S. Narumiya,et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice , 2001, Nature Medicine.
[9] J. Morrow,et al. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. , 1999, Cancer research.
[10] Rajnish A. Gupta,et al. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.
[11] J. Regan,et al. Phosphorylation of Glycogen Synthase Kinase-3 and Stimulation of T-cell Factor Signaling following Activation of EP2 and EP4 Prostanoid Receptors by Prostaglandin E2 * , 2002, The Journal of Biological Chemistry.
[12] R Day,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[13] C. Harris,et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. , 2003, Cancer research.
[14] Andrew J. Dannenberg,et al. Regulation of Cyclooxgenase-2 mRNA Stability by Taxanes , 2003, Journal of Biological Chemistry.
[15] B. Evers,et al. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. , 2003, Cancer research.
[16] L. Norton,et al. Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer , 2002, The Journal of Biological Chemistry.
[17] R. DuBois,et al. Prostaglandin E2 Regulates Cell Migration via the Intracellular Activation of the Epidermal Growth Factor Receptor* , 2003, Journal of Biological Chemistry.
[18] Michael J Thun,et al. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.
[19] G. Gasparini,et al. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? , 2003, The Lancet. Oncology.
[20] P. Anderson,et al. TIA‐1 is a translational silencer that selectively regulates the expression of TNF‐α , 2000 .
[21] F. Ranelletti,et al. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] Yukihiko Sugimoto,et al. Host Prostaglandin E2-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth , 2003, The Journal of experimental medicine.
[23] D. Yankelevitz,et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Garavito,et al. Cyclooxygenases: structural, cellular, and molecular biology. , 2000, Annual review of biochemistry.
[25] H. Choy,et al. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? , 2003, Journal of the National Cancer Institute.
[26] T. Hla,et al. The RNA-binding Protein HuR Regulates the Expression of Cyclooxygenase-2* , 2003, Journal of Biological Chemistry.
[27] J. Isola,et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. , 2002, Cancer research.
[28] A. Tarnawski,et al. Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy , 2002, Nature Medicine.
[29] M. Huang,et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] O. Boutaud,et al. Tristetraprolin Binds to the 3′-Untranslated Region of Cyclooxygenase-2 mRNA , 2003, The Journal of Biological Chemistry.
[31] R. Langenbach,et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. , 2000, Cancer research.
[32] J. Morrow,et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. , 2003, The Journal of clinical investigation.
[33] P. Anderson,et al. Regulation of Cyclooxygenase-2 Expression by the Translational Silencer TIA-1 , 2003, The Journal of experimental medicine.
[34] T. Hla,et al. Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.
[35] N. Altorki,et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. , 2001, The Lancet. Oncology.
[36] D. Goldenberg,et al. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. , 2002, Cancer research.
[37] K. Subbaramaiah,et al. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. , 2003, Trends in pharmacological sciences.
[38] S. Dey,et al. Host cyclooxygenase-2 modulates carcinoma growth. , 2000, The Journal of clinical investigation.
[39] T. Iwama,et al. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.